Category Events
10th Antibody Industrial Symposium 2022 We are proud to announce our participation to the 10th Antibody Industrial Symposium 2022 (AIS2022) that will be held from 28th to 29th June 2022 in person in Montpellier, France. https://aiscongress.com
Henry-Vincent Charbonné (1953-2021)
NanoMedSyn is classified as a DEEPTECH company by Bpifrance for its Innovative Therapeutic Targeting Technology.
NanoMedSyn has signed a research agreement with the French National Research Agency within the framework of the « Plan France Relance Préservation de l’Emploi de R&D ». This agreement concerns a two-year collaborative research project with a CNRS institute in Montpellier, the Max Mousseron Institute of Biomolecules.
NanoMedSyn has been distinguished for its Growth Path by Bpifrance and joins the « Excellence » community.
NanoMedSyn has signed a 3-year Innovation Contract with the Occitanie Region for a « Research and Development of New Targeted Drugs » project
Dr. Marcel Garcia, co-founder and Scientific Director, is appointed President and Scientific Director of NanoMedSyn by the General Assembly. This appointment follows the retirement of the President Henry-Vincent Charbonné for health reasons. Henry has presided remarkably over the company for 5 years and brought all his previous expertise acquired in large pharmaceutical companies. In particular,
This article demonstrates the involvement of acid phosphatases in the higher efficacy of AMFA-labelled enzyme therapy. J Cell Mol Med. 2019;23:6499-6503.
Shire and NanomedSyn enter into research agreement for potential lysosomal storage disorder treatment. This collaboration was stopped in September 2019. ShireNanoMedSyn_PressRelease
NanoMedSyn develops an efficient treatment for refractory Pompe disease published by Journal of Controlled Release. J Control Release 2017, 269:15-23.